CIN 108
Alternative Names: CIN-108Latest Information Update: 27 Oct 2022
At a glance
- Originator CinSano Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action DCUN1D1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Oct 2022 CinRx Pharma plans a regulatory submission in 2023 (CinRx Pharma website, October 2022)
- 27 Oct 2022 CinRx Pharma plans a clinical trial for Cancer in 2023 (CinRx Pharma website, October 2022)
- 03 Aug 2022 Preclinical trials in Cancer in USA (unspecified route) prior to August 2022 (CinRx Pharma pipeline, August 2022)